FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514181> ?p ?o ?g. }

• W4365514181 endingPage "CT002" @default.
• W4365514181 startingPage "CT002" @default.
• W4365514181 abstract "Abstract Background: The phase 1/2 KEYMAKER-U02 substudy 02C (NCT04303169) is evaluating neoadjuvant pembro + investigational agents or pembro alone followed by adjuvant pembro in stage IIIB-D melanoma. Results from patients treated with neoadjuvant pembro (anti-PD-1) + vibo (anti-TIGIT; arm 1), pembro + geba (coxsackievirus A21; arm 2), or pembro alone (arm 3) are presented. Methods: Eligible patients were ≥18 y with resectable stage IIIB, IIIC, or IIID melanoma per AJCC 8th ed criteria, ≥1 measurable lesion per RECIST v1.1, and ECOG PS ≤1. Patients were randomly allocated across open investigational arms. Before resection, patients in arm 1 received 2 administrations of pembro 200 mg Q3W + vibo 200 mg Q3W (cycle 1, day 1; cycle 2, day 1); patients in arm 2 received 1 administration of pembro 400 mg (cycle 1, day 8) + 5 administrations of geba at a fixed dose of 3 × 108 tissue culture infectious dose 50% during cycle 1 (days 1, 3, 5, 8, and 22); and patients in arm 3 received 1 administration of pembro 400 mg. Surgical resection was performed at week 6. At week 12, patients started adjuvant pembro 400 mg Q6W for ≤8 administrations (total treatment duration, ~1 y). Primary end points were safety and tolerability and pCR rate by central review. Secondary end points were near pCR rate and pPR rate by central review and RFS by investigator review. ORR per RECIST v1.1 and EFS by investigator review were exploratory. Results: At data cutoff (September 9, 2022), 66 patients had been assigned to treatment (arm 1 [pembro + vibo], n = 26; arm 2 [pembro + geba], n = 25; arm 3 [pembro alone], n = 15). Median follow-up was 14.1 mo (range, 8.0-26.1). Treatment-related AEs occurred in 92% of patients in arm 1, 84% in arm 2, and 80% in arm 3. Grade 3/4 treatment-related AEs occurred in 8%, 24%, and 7% of patients, respectively, with no grade 5 treatment-related AEs. 3 patients (12%) in arm 1, 5 (20%) in arm 2, and 0 in arm 3 discontinued any drug because of treatment-related AEs. Immune-mediated AEs or infusion reactions were reported in 31% of patients in arm 1, 32% in arm 2, and 27% in arm 3. The pCR rate was 38% (95% CI, 20-59) in arm 1, 28% (12-49) in arm 2, and 40% (16-68) in arm 3; the near pCR rate was 12% (2-30), 12% (3-31), and 7% (&lt;1-32), respectively; and the pPR rate was 31% (14-52), 12% (3-31), and 27% (8-55), respectively. Median RFS was not reached in any arm; 18-mo RFS rates were 95% (95% CI, 70-99) in arm 1, 87% (56-97) in arm 2, and 73% (24-93) in arm 3. ORR was 50% (95% CI, 30-71), 32% (15-54), and 27% (8-55), respectively. Median EFS was not reached in any arm; 18-mo EFS rates were 81% (95% CI, 60-92), 61% (38-78), and 79% (47-93), respectively. Conclusions: Neoadjuvant pembro + vibo, pembro + geba, and pembro alone followed by adjuvant pembro had manageable safety and promising antitumor activity in patients with stage IIIB-D melanoma. Of the combination treatments, pembro + vibo showed the most promise. Citation Format: Reinhard Dummer, Caroline Robert, Richard A. Scolyer, Janis M. Taube, Michael T. Tetzlaff, Andrew Hill, Jean-Jacques Grob, David C. Portnoy, Celeste Lebbe, Muhammad A. Khattak, Jonathan Cohen, Gil Bar-Sela, Inderjit Mehmi, Ronnie Shapira Frommer, Nicolas Meyer, Yixin Ren, Mizuho Fukunaga-Kalabis, Clemens Krepler, Georgina V. Long. KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT002." @default.
• W4365514181 created "2023-04-15" @default.
• W4365514181 creator A5002640207 @default.
• W4365514181 creator A5004690917 @default.
• W4365514181 creator A5005744947 @default.
• W4365514181 creator A5022449574 @default.
• W4365514181 creator A5025478490 @default.
• W4365514181 creator A5029072392 @default.
• W4365514181 creator A5035471137 @default.
• W4365514181 creator A5037620517 @default.
• W4365514181 creator A5052672458 @default.
• W4365514181 creator A5058314094 @default.
• W4365514181 creator A5061072132 @default.
• W4365514181 creator A5061348179 @default.
• W4365514181 creator A5063825320 @default.
• W4365514181 creator A5067794998 @default.
• W4365514181 creator A5067831105 @default.
• W4365514181 creator A5069462704 @default.
• W4365514181 creator A5070576000 @default.
• W4365514181 creator A5088007604 @default.
• W4365514181 creator A5089297467 @default.
• W4365514181 date "2023-04-14" @default.
• W4365514181 modified "2023-10-17" @default.
• W4365514181 title "Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma" @default.
• W4365514181 doi "https://doi.org/10.1158/1538-7445.am2023-ct002" @default.
• W4365514181 hasPublicationYear "2023" @default.
• W4365514181 type Work @default.
• W4365514181 citedByCount "3" @default.
• W4365514181 countsByYear W43655141812023 @default.
• W4365514181 crossrefType "journal-article" @default.
• W4365514181 hasAuthorship W4365514181A5002640207 @default.
• W4365514181 hasAuthorship W4365514181A5004690917 @default.
• W4365514181 hasAuthorship W4365514181A5005744947 @default.
• W4365514181 hasAuthorship W4365514181A5022449574 @default.
• W4365514181 hasAuthorship W4365514181A5025478490 @default.
• W4365514181 hasAuthorship W4365514181A5029072392 @default.
• W4365514181 hasAuthorship W4365514181A5035471137 @default.
• W4365514181 hasAuthorship W4365514181A5037620517 @default.
• W4365514181 hasAuthorship W4365514181A5052672458 @default.
• W4365514181 hasAuthorship W4365514181A5058314094 @default.
• W4365514181 hasAuthorship W4365514181A5061072132 @default.
• W4365514181 hasAuthorship W4365514181A5061348179 @default.
• W4365514181 hasAuthorship W4365514181A5063825320 @default.
• W4365514181 hasAuthorship W4365514181A5067794998 @default.
• W4365514181 hasAuthorship W4365514181A5067831105 @default.
• W4365514181 hasAuthorship W4365514181A5069462704 @default.
• W4365514181 hasAuthorship W4365514181A5070576000 @default.
• W4365514181 hasAuthorship W4365514181A5088007604 @default.
• W4365514181 hasAuthorship W4365514181A5089297467 @default.
• W4365514181 hasConcept C126322002 @default.
• W4365514181 hasConcept C197934379 @default.
• W4365514181 hasConcept C2778375690 @default.
• W4365514181 hasConcept C71924100 @default.
• W4365514181 hasConceptScore W4365514181C126322002 @default.
• W4365514181 hasConceptScore W4365514181C197934379 @default.
• W4365514181 hasConceptScore W4365514181C2778375690 @default.
• W4365514181 hasConceptScore W4365514181C71924100 @default.
• W4365514181 hasIssue "8_Supplement" @default.
• W4365514181 hasLocation W43655141811 @default.
• W4365514181 hasOpenAccess W4365514181 @default.
• W4365514181 hasPrimaryLocation W43655141811 @default.
• W4365514181 hasRelatedWork W1506200166 @default.
• W4365514181 hasRelatedWork W1995515455 @default.
• W4365514181 hasRelatedWork W2048182022 @default.
• W4365514181 hasRelatedWork W2080531066 @default.
• W4365514181 hasRelatedWork W2604872355 @default.
• W4365514181 hasRelatedWork W2748952813 @default.
• W4365514181 hasRelatedWork W2899084033 @default.
• W4365514181 hasRelatedWork W3031052312 @default.
• W4365514181 hasRelatedWork W3032375762 @default.
• W4365514181 hasRelatedWork W3108674512 @default.
• W4365514181 hasVolume "83" @default.
• W4365514181 isParatext "false" @default.
• W4365514181 isRetracted "false" @default.
• W4365514181 workType "article" @default.